{"nctId":"NCT04729621","briefTitle":"A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis","startDateStruct":{"date":"2021-03-22","type":"ACTUAL"},"conditions":["Osteoporosis, Postmenopausal"],"count":332,"armGroups":[{"label":"TVB-009 main treatment period","type":"EXPERIMENTAL","interventionNames":["Combination Product: TVB-009"]},{"label":"PROLIA main treatment period","type":"ACTIVE_COMPARATOR","interventionNames":["Combination Product: Prolia®"]},{"label":"TVB-009 main / TVB-009 transition period","type":"EXPERIMENTAL","interventionNames":["Combination Product: TVB-009"]},{"label":"PROLIA main / PROLIA transition period","type":"ACTIVE_COMPARATOR","interventionNames":["Combination Product: Prolia®"]},{"label":"PROLIA main / TVB-009 transition period","type":"EXPERIMENTAL","interventionNames":["Combination Product: TVB-009","Combination Product: Prolia®"]}],"interventions":[{"name":"TVB-009","otherNames":[]},{"name":"Prolia®","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Postmenopausal womeen (≥60 and ≤90 years) with a diagnosis of osteoporosis\n* Body weight ≥50 kg and ≤90 kg\n* Bone Mineral Density (BMD) measurement T score of less than -2.5 but not less than -4.0 by dual-energy X-ray absorptiometry (DXA) at the lumbar spine at screening\n* At least 3 vertebrae in the L1 L4 region that are evaluable by dual-energy X-ray absorptiometry (DXA)\n\nExclusion Criteria:\n\n* One severe or more than two moderate vertebral fractures\n* History and/or presence of hip fracture or atypical femur fracture\n* Any prior treatment with denosumab\n* Ongoing use of any bone active drugs which can affect Bone Mineral Density (BMD)\n* Vitamin D deficiency or hyper- or hypocalcemiacium at screening\n* Hyperthyroidism, hypothyroidism, hypoparathyroidism or hyperparathyroidism\n* Any medical condition that could jeopardize or would compromise the patient's safety or ability to participate in this study\n\nOther Inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"60 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in LS-BMD at Week 52","description":"Percent change from baseline in lumbar spine bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 52","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.76","spread":null},{"groupId":"OG001","value":"4.54","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in sCTX-1 at Week 26","description":"Percent change from baseline in serum C-telopeptide cross-link of type 1 collagen at week 26","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-56.05","spread":null},{"groupId":"OG001","value":"-65.13","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in LS-BMD at Week 26","description":"Percent change from baseline in lumbar spine bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 26","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.70","spread":"4.294"},{"groupId":"OG001","value":"3.62","spread":"3.815"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Femoral Neck BMD at Week 26","description":"Percent change from baseline in femoral neck bone mineral density (BMD) based on centrally assessed dual energy X ray absorptiometry (DXA)at week 26","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.87","spread":"4.877"},{"groupId":"OG001","value":"2.01","spread":"3.611"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Hip BMD at Week 26","description":"Percent change from baseline in total hip bone mineral density (BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 26","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.89","spread":"3.488"},{"groupId":"OG001","value":"2.02","spread":"2.526"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in sCTX-1","description":"Percent change from baseline in serum C-telopeptide cross-link of type 1 collagen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-57.91","spread":"44.161"},{"groupId":"OG001","value":"-68.80","spread":"35.846"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participatns With sCTX-1 Suppression at Week 4","description":"Proportion of patients with suppression of serum C-telopeptide cross-link of type 1 collagen at week 4","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.2","spread":null},{"groupId":"OG001","value":"94.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in P1NP","description":"Percent change from baseline in procollagen type 1 N propeptide (P1NP) to Week 52","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-56.43","spread":"35.431"},{"groupId":"OG001","value":"-62.03","spread":"33.712"}]}]}]},{"type":"SECONDARY","title":"Number of Fractures up to Week 52","description":"Number of patients with who experienced any new fractures up to week 52.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Week 52 in LS-BMD by DXA at Week 78","description":"Percent change from week 52 in lumbar spine bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 78","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.82","spread":"3.120"},{"groupId":"OG001","value":"1.15","spread":"3.440"},{"groupId":"OG002","value":"1.24","spread":"3.069"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Week 52 in Femoral Neck BMD by DXA at Week 78","description":"Percent change from week 52 in femoral neck bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 78","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":"3.525"},{"groupId":"OG001","value":"0.80","spread":"3.560"},{"groupId":"OG002","value":"0.94","spread":"3.082"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Week 52 in Total Hip BMD by DXA at Week 78","description":"Percent change from week 52 in total hip bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 78","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"2.089"},{"groupId":"OG001","value":"0.66","spread":"2.109"},{"groupId":"OG002","value":"0.27","spread":"2.264"}]}]}]},{"type":"SECONDARY","title":"Difference Between Percent Change From Baseline in sCTX-1 Between Week 52 and Week 78","description":"Difference in the percent change from baseline in serum C-telopeptide cross-link of type 1 collagen from baseline to Week 78 as compared to baseline to Week 52","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.95","spread":"41.612"},{"groupId":"OG001","value":"13.17","spread":"28.558"},{"groupId":"OG002","value":"7.55","spread":"36.509"}]}]}]},{"type":"SECONDARY","title":"Difference Between Percent Change From Baseline in P1NP Between Week 52 and Week 78","description":"The difference in the Percent change from baseline in procollagen type 1 N propeptide at Week 78 compared to Week 52.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.95","spread":"23.376"},{"groupId":"OG001","value":"4.83","spread":"14.551"},{"groupId":"OG002","value":"2.89","spread":"39.804"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Fractures Between Week 52 and Week 78","description":"Number of patients experiencing new fractures between week 52 and week 78","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Adverse Event","description":"Number of patients reporting at least one treatment-emergent adverse event up to week 52","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"13","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"95","spread":null}]},{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Adverse Events in the Transition Period","description":"Number of patients reporting at least one treatment-emergent adverse event between weeks 52 and 78","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"26","spread":null}]},{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"52","spread":null},{"groupId":"OG002","value":"45","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Antidrug Antibodies (ADAs) in the Main Treatment Period","description":"Number of patients with confirmed positive antidrug antibodies (ADAs) post-baseline through Week 52","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"25","spread":null}]},{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"11","spread":null}]},{"measurements":[{"groupId":"OG000","value":"147","spread":null},{"groupId":"OG001","value":"129","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Antidrug Antibodies (ADAs) in the Transition Period","description":"Number of patients with confirmed positive antidrug antibodies (ADAs) at Week 65","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"133","spread":null},{"groupId":"OG001","value":"61","spread":null},{"groupId":"OG002","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Femoral Neck BMD at Week 52","description":"Percent change from baseline in femoral neck bone mineral density (BMD) based on centrally assessed dual energy X ray absorptiometry (DXA)at week 52","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.39","spread":"5.795"},{"groupId":"OG001","value":"2.34","spread":"3.780"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Hip BMD at Week 52","description":"Percent change from baseline in total hip bone mineral density (BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 52","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.67","spread":"3.981"},{"groupId":"OG001","value":"3.00","spread":"2.768"}]}]}]},{"type":"SECONDARY","title":"Number of TEAEs Leading to Patient Withdraw From the Study","description":"Number of patients that withdraw or are removed from the study due to treatment emergent adverse events from both the main and transition treatment periods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Local Tolerability at Injection Site","description":"Number of patients who report Injection Site Reactions at Day 1, Week 26, or Week 52.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"144","spread":null},{"groupId":"OG001","value":"145","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"142","spread":null},{"groupId":"OG001","value":"142","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"2","spread":null}]},{"measurements":[{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null}]},{"measurements":[{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"3","spread":null},{"groupId":"OG004","value":"0","spread":null}]},{"measurements":[{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"1","spread":null}]},{"measurements":[{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"0","spread":null}]},{"measurements":[{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"1","spread":null}]},{"measurements":[{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"3","spread":null}]},{"measurements":[{"groupId":"OG002","value":"133","spread":null},{"groupId":"OG003","value":"59","spread":null},{"groupId":"OG004","value":"63","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":166},"commonTop":["Vitamin D deficiency","COVID-19","Hypercalcaemia","Headache","Arthralgia"]}}}